Ionis Pharma (IONS) Stock Forecast & Price Target

Ionis Pharmaceuticals is positioned favorably because its platform has repeatedly converted into approved therapies across neurology, cardiovascular, and rare disease markets, validating both the antisense technology and the company’s ability to advance assets with real commercial potential. The recent Phase 3 win for sefaxersen in a 459-patient study, plus the 73-patient FUSION success for ulefnersen, expands near-term regulatory optionality and adds royalty upside, while Tryngolza’s strong launch economics could be especially meaningful given modeled peak U.S. sales of about $4B and a large 3M-patient severe hypertriglyceridemia population. With additional launches already achieved in 2024 and 2025, and royalty streams that can reach the high teens to 20% on sefaxersen net sales, the company’s diversified pipeline and growing commercial base support a constructive fundamental outlook.

Ionis Pharmaceuticals is viewed negatively because the model now assigns 0% probability of success to pelacarsen after the Lp(a)-HORIZON failure, eliminating value from a major program and underscoring the fragility of the pipeline. Even where assumptions improved, such as Zanvastro with 100% PoS and an estimated peak annual revenue of about $160M, the broader valuation remains constrained by a 0% terminal growth rate, 8.8% WACC, and no value assigned to other clinical or pre-clinical assets. The outlook is also pressured by biotech-wide execution, regulatory, financing, and IP risks, plus company-specific uncertainty around clinical delays, safety, efficacy, and approval timing.